Practical considerations in the establishment of psychedelic research programs

Interest in the therapeutic potential of psychedelics has grown substantially alongside increasing industry, state, and federal support. However, psychedelics' intense psychoactive effects, Schedule I status under US federal law, and historical stigma create distinctive regulatory, operational, and community-relations challenges for investigators seeking to conduct research at academic medical centres. While the US Food and Drug Administration has issued non-binding recommendations on clinical trial design and personnel qualifications, the authors note a lack of practical, on-the-ground guidance for building the infrastructure required to run psychedelic studies. Murnane and colleagues set out to fill that gap by distilling the academic literature and the authors' combined experiences—ranging from basic science and investigator-initiated trials to industry-sponsored trials and prior employment at regulatory agencies—into a practical guide. The article aims to outline common obstacles and concrete steps investigators and administrators should anticipate when establishing psychedelic research programmes in US academic medical centres, including regulatory, logistical, staffing, and community-engagement considerations.

The extracted text indicates this manuscript is a narrative, experience-informed review rather than a formal systematic review or primary empirical study. The authors reviewed relevant academic literature and supplemented that with observations drawn from their direct experience conducting basic science studies, investigator-initiated trials, industry trials, or working at the FDA or DEA. The paper organises practical recommendations across operational domains (institutional engagement, regulatory permitting, pharmacy collaboration, facilities, staffing, and community engagement). The extraction does not provide details of a structured search strategy, inclusion/exclusion criteria, or formal risk-of-bias assessment. Therefore, the methods appear to rely on selective literature review combined with authors' experiential knowledge and illustrative examples rather than systematic evidence synthesis.

The body of the paper presents actionable recommendations and operational considerations across multiple domains. Key points reported by the authors include: Institutional support and governance: Investigators should cultivate broad institutional buy-in early, consulting department chairs, research leadership (e.g. Director of Research, Vice-Chancellor for Research), regulatory affairs offices, and clinical departments that will be involved. Multidisciplinary outreach and educational sessions can reduce stigma and pre-empt concerns; creating an institutional psychedelic research interest group may help build collaborations and awareness. Funding: Securing funding for investigator-initiated psychedelic research remains challenging. Historically, non-profit organisations and philanthropists funded much work, but commercialisation has changed donor behaviour. Governmental funding from NIMH, NIDA, the Department of Veterans Affairs, and the Department of Defense is increasing, yet competition is high. The authors advise exploring internal institutional support and philanthropy while avoiding overstated claims to potential donors. Pharmacy collaboration and controlled substance management: Early engagement with institutional pharmacy services is essential. Investigational drug services typically manage receipt and secure storage, but some pharmacies may be unwilling or unable to handle Schedule I drugs without additional state permissions. Investigators must develop SOPs with pharmacy covering delivery, access controls, temperature monitoring, inventory reconciliation, documentation, transport, sequestration, and destruction or return procedures. The DEA requires drug accountability logs and other documentation. Although the CFR mandates biennial inventory, the authors recommend monthly inventories as best practice. Study spaces and treatment environment: Treatment rooms should be quiet, aesthetically calming (resembling living rooms), minimise visible medical equipment, and include features that reduce risks (e.g. ensuite or nearby private restroom without mirrors, locked/shatter-resistant windows and artwork). Lighting, sound sources, Wi‑Fi for music and data collection, and emergency planning should be addressed. Placement of secure study drug storage close to administration areas is strongly advised to minimise complex transport and chain-of-custody burdens. Security and equipment: Storage requirements differ for practitioners versus non-practitioners under federal regulations; investigators should consult 21 CFR §1301.72 and their local Diversion Investigator. Where required, medication-dispensing systems (e.g. Pyxis™) may be acceptable but can conflict with therapeutic aesthetics and may need backup power and networking. Although some facilities may request an automated external defibrillator or an ACLS-trained clinician nearby, the authors note no psychedelic clinical trial they are aware of has required use of AEDs, BLS, MET, or ACLS during sessions. External collaborators and personnel training: Investigators may need outside expertise in toxicology, biostatistics, chemistry, CMC (chemistry, manufacturing and controls), regulatory strategy, and project management. Companies and consultants exist that specialise in IND preparation, DEA interactions, and therapist training for psychedelic-assisted therapy. Regulatory submissions and INDs: The paper outlines IND considerations for both investigator-initiated and sponsor-submitted INDs. Essential IND components include an investigational plan, clinical protocol, investigator brochure, CMC data, and pharmacology/toxicology data. The FDA has a 30-calendar-day review window after IND receipt during which it may issue comments or place a clinical hold. The authors recommend not submitting an IND when rapid response to FDA queries would be impractical. Selecting suppliers with a Drug Master File (DMF) on file with the FDA and prior IND support can considerably simplify the CMC burden for IITs. Schedule I researcher registration and DEA process: Investigators must submit DEA Form 225 via the RICS portal with supporting attachments (cover letter describing site and quantities, site security agreements, reverse distributor information, etc.). After federal review an on-site inspection by a local DEA Diversion Investigator typically follows; inspection practices and interpretations vary considerably by investigator. Adding a new Schedule I drug to an existing registration requires supplemental documentation and may be performed as a registration update. DEA Form 222 is used to order and transfer Schedule I–II substances; logistical coordination is required for receipt by institutional receiving services. Importation and supply chain: Due to a limited number of DEA-registered US manufacturers for Schedule I psychedelics, investigators may need to import drug supplied from the UK, Canada, or elsewhere. Import permits (DEA Form 357) and coordination with DEA-registered importers/distributors and customs are required; the import permitting process usually takes about 30 days. Manufacturing formats vary (bulk powder, encapsulated doses), and choices affect whether additional manufacturing/relabelling steps require DEA-registered facilities. Informed consent, medication tapers, and participant safety: Consent documents should describe common acute effects, rarer but serious risks (psychosis, suicidality, hallucinogen persisting perception disorder, serotonin syndrome, seizures), reproductive risks, and the potential for enduring personality or worldview changes. Medication tapering prior to dosing is common and its risks must be explained. Rescue medications (e.g. benzodiazepines, second‑generation antipsychotics with 5‑HT2A antagonism such as risperidone or olanzapine) should be available and planned for, though the authors note benzodiazepines might attenuate putative antidepressant effects and FGAs may be suboptimal. Session logistics, staffing, and EMR integration: Because sessions are lengthy and require at least one monitor per participant, staffing schedules and backup monitors are necessary. Physicians are often required to complete discharge checklists. The study team should integrate study flows into the electronic medical record (new treatment contexts, order sets for study drug and as‑needed medications) and ensure Wi‑Fi and cybersecurity approvals for remote or tablet-based assessments. Laboratory specimens and point-of-care testing: Investigators must confirm onsite centrifugation and freezer capacities for specimen processing and storage or arrange courier access to satellite facilities. Point-of-care urine/breath/pregnancy testing with quick turnaround is often required prior to dosing; institutional point-of-care testing approvals or CLIA considerations may apply. Recruitment, expectancy, and participant management: Trials commonly face recruitment challenges arising from stigma, media hype, restrictive inclusion criteria (e.g. medication taper requirements), and geographic mismatch between interested volunteers and study sites. Expectancy effects and disappointment—especially around placebo allocation—are frequent; strategies such as open-label crossover designs can be used in some trials. The authors recommend IRB-approved self-screening tools to reduce coordinator burden. Drug accountability and disposal: Procedures for destruction or return of unused Schedule I materials must be specified; reverse distributor relationships and DEA reporting rules affect how blinded or unblinded returns are handled. Animal and preclinical materials exposed to Schedule I substances may also require particular disposal processes. Unusual institutional and community responses: The authors give illustrative examples of administrative, legal, or community misunderstandings—from contractual delays due to erroneous legal concerns, to IRB scrutiny of music playlists, to false claims by third parties—that underscore the need for proactive communications and community engagement. Preclinical research considerations: Non-human research with Schedule I substances has its own regulatory and disposal complexities; animal tissues exposed to Schedule I drugs may be subject to DEA disposal requirements. Overall, the paper provides operational detail and timelines to help investigators anticipate sources of delay and regulatory burden—examples include protocol-to-first-dose timelines of one to two years or longer, an FDA IND review window of 30 days, and an import permitting process of about 30 days—though these timeframes can vary by site and circumstance.

Across the sections, the authors interpret their synthesis as practical, experience-based counsel: establishing psychedelic research programmes requires early, sustained engagement with institutional leadership, pharmacy, regulatory experts, and community stakeholders to navigate regulatory complexity and reduce delays. They stress maintaining scientific objectivity and avoiding the quasi‑religious rhetoric sometimes associated with the broader psychedelic movement. In discussions about funding and donor engagement, the authors caution against overstating therapeutic benefits and recommend transparent communication about uncertainties and costs. The manuscript highlights several sources of uncertainty and variability that limit generalisability of any single site's experience: institutional heterogeneity in infrastructure and oversight, divergent interpretations by local DEA Diversion Investigators, differing state-level licensing requirements, and variability in sponsor or supplier practices. The authors acknowledge recruitment limitations arising from stigma, media-driven expectancy, and demographic imbalances among volunteers, and they note logistic limitations such as supply-chain delays for equipment and the variable willingness of pharmacy services to manage Schedule I drugs. Practical implications the authors discuss include the need to prepare SOPs for drug handling and session logistics, to select drug suppliers carefully with attention to CMC documentation and DMF status when possible, and to build relationships with regulatory consultants or collaborators when institutional resources are lacking. They recommend anticipating extended timelines, designing contingency plans for unannounced inspections or shipment issues, and including community consultation as part of programme development. The authors position these measures as means to make psychedelic research feasible in academic settings despite sociopolitical and regulatory obstacles.

The extracted Conclusion is incomplete and ends abruptly. From the material present and the authors' earlier statements, the concluding message is that conducting research with psychedelics is more complex than typical behavioural or daily‑medication trials because of regulatory, logistical, and sociopolitical challenges. However, the authors maintain that these challenges are likely surmountable with advance planning, persistence, adherence to regulatory requirements, and assistance from institutional colleagues and external experts. The extracted text does not contain the paper's full, final concluding paragraph, so additional concluding detail from the original document is not available in this extraction.